Duramycin is a cyclic peptide lantibiotic derived from Streptomyces cinnamoneuma. Duramycin interacts with phosphatidylethanolamine (PE) and has antibacterial, antiviral effects. Duramycin stimulates chloride secretion in airway epithelium and has the potential for cystic fibrosis treatment.
BI-1950 is a highly potent lymphocyte function associated antigen-1 (LFA-1) inhibitor and the LFA-1 is an essential component in normal immune system function and a target for drug discovery[1].